Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 725.7% in March

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 28,900 shares, an increase of 725.7% from the February 29th total of 3,500 shares. Based on an average daily volume of 91,700 shares, the short-interest ratio is presently 0.3 days. Currently, 5.5% of the shares of the company are sold short.

Aptevo Therapeutics Trading Up 1.2 %

APVO stock opened at $4.06 on Thursday. The firm has a 50 day moving average of $6.12 and a 200-day moving average of $9.24. Aptevo Therapeutics has a 12-month low of $3.81 and a 12-month high of $92.62.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Aptevo Therapeutics in a research report on Monday. They issued a “hold” rating for the company.

Institutional Investors Weigh In On Aptevo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of APVO. Sabby Management LLC acquired a new stake in shares of Aptevo Therapeutics during the 3rd quarter valued at approximately $440,000. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics during the 3rd quarter worth approximately $408,000. Citadel Advisors LLC purchased a new position in shares of Aptevo Therapeutics during the 4th quarter worth approximately $47,000. Cantor Fitzgerald L. P. increased its stake in shares of Aptevo Therapeutics by 14.8% during the 2nd quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 32,422 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Aptevo Therapeutics during the 1st quarter worth approximately $152,000. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.